Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) shares hit a new 52-week low on Tuesday . The company traded as low as $12.98 and last traded at $13.97, with a volume of 141904 shares trading hands. The stock had previously closed at $14.81.
Rapport Therapeutics Stock Up 5.1 %
The business’s 50 day moving average price is $20.26 and its 200-day moving average price is $21.42.
Institutional Investors Weigh In On Rapport Therapeutics
A number of institutional investors have recently modified their holdings of the company. Values First Advisors Inc. purchased a new stake in Rapport Therapeutics during the third quarter worth about $31,000. BNP Paribas Financial Markets purchased a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $34,000. JPMorgan Chase & Co. purchased a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $83,000. SG Americas Securities LLC acquired a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $101,000. Finally, Sandia Investment Management LP purchased a new position in Rapport Therapeutics in the 2nd quarter valued at approximately $116,000.
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Further Reading
- Five stocks we like better than Rapport Therapeutics
- 3 Small Caps With Big Return Potential
- Penny Stock BranchOut Food: Why It Won’t Stay Cheap for Long
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Bull Case for Transocean Stock: 100% Upside Could Be Within Reach
- How to Plot Fibonacci Price Inflection Levels
- Advance Auto Parts: Retail Trends Suggest Big Gains Ahead
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.